All posts by imreal

From Joyce to Grace” recounts the author’s poignant life and her fortitude in faith and trust in God


News Image

“Grace: From Joyce to Grace”: an emotionally driven story of the author’s moments of heartache and determination from God that brought grace to her soul. “Grace: From Joyce to Grace” is the creation of published author Grace Neils Woodbridge, a minister, missionary, certified marriage and pre-marriage coach, and teacher.

Woodbridge shares, “God can transform a life from nothing and make something beautiful out of it. My childhood life was hopeless. I didn’t stand a chance to survive life and be an adult. I had no hope. I didn’t know what it was like to have hope. I was tossed back and forth living from one family member to another. Then I grew to be a teenager, and at fifteen years old, I was raped, and my future was taken from me by rape, and I got pregnant and gave birth to a child. I was a mother before I became an adult. I had no experience about life, and there seem to be no future. Then I had a relationship and lived in a battered relationship.

“One day, after I was beaten so badly, my eyes swollen and my head swollen, I lay on the floor, and I cried out to God, ‘If this is what life is, I don’t want to live anymore. Take me. I want to die!’ Then quietly within me, I heard, ‘It doesn’t have to be that way. Leave.’ I didn’t think before that I could leave permanently because I left once with the children, and he came and took us back, but God gave me the strength that I needed, and He directed me how to escape, and I was set free from marital abuse, and through God’s grace, He made something beautiful out of me, and my life was transformed from nothing to something good. I will always give God the praise for his goodness, his mercy, and his grace to (me) Grace all the days of my life!”

Published by Christian Faith Publishing, Grace Neils Woodbridge’s new book is a testament to the benevolence of God that heals the afflicted and grants repose to those who seek His light in the face of adversity and malady.

This book bears a striking proof of God’s unconditional love and mercy that beckons the persecuted and abused into His saving arms.

View the synopsis of “Grace: From Joyce to Grace” on YouTube.

Consumers can purchase “Grace: From Joyce to Grace” at traditional brick-and-mortar bookstores or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Grace: From Joyce to Grace,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Author Sonise Carri’s newly released “Write It Down and Make It Plain” is an inspirational 90-day journal designed to help readers achieve their life goals


News Image

“Write It Down and Make It Plain”: a straight-talking and highly practical guide to overcoming the perceived obstacles that stand in the way of self-realization and personal greatness. “Write It Down and Make It Plain” is the creation of published author, Sonise Carri, a Certified Christian Life Coach, motivational speaker, and mentor.

Carri writes: “With the challenges we face day today, it is essential that we walk with a renewed and sound mind. We can no longer depend on our own knowledge. There must be a dependency on God who is the author and finisher of our faith; to direct and lead us to peace, continual joy, and wisdom to maneuver in the current world we live in.”

Published by Christian Faith Publishing, Sonise Carri’s new book is a 90-day journal that aims to help readers learn to employ faith, consistency, and self-discipline in order to overcome the obstacles that lie between them and achieving their desired goals.

Throughout using this guide, readers will not only find the motivation needed to set and achieve lifelong goals, but also discover that embarking on this journey to self-realization is the first step to living a life increasingly blessed with a previously unknown plentitude of peace, joy, and wisdom.

View a synopsis of “Write It Down and Make It Plain” on YouTube.

Consumers can purchase “Write It Down and Make It Plain” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Write It Down and Make It Plain”, contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Regulation, Compliance, and Best Practices Webinar July 29, 2020


WCG FDAnews

WCG FDAnews

Searching for the best way to fulfill the competing needs of various device identification requirements? Looking for the most efficient way to appropriately identify a product in different global markets?

The task of meeting unique device identification (UDI) guidelines can be complicated. Requirements around the world are evolving and despite efforts by the Global Harmonization Task Force and International Medical Device Regulator Forum to integrate global expectations, they are evolving in different ways in different places.

Even now, when the deadline for final implementation of Class I products is quickly approaching in the United States and UDI timelines in the EU remain unchanged due to COVID-19, regulatory bodies in other countries are starting to implement their own new programs.

UDI expert Jay Crowley will share ways to manage multiple regulatory bodies, best practices around establishing and maintaining robust and effective global UDI processes, possible responses to distinct local UDI concerns and how to submit identification product data to various stakeholders:

The Evolution of Universal Device Identification Guidelines:


  • Impacts on device identification and product data
  • Global development and implementation of UDI requirements
  • Recommended shared data obligations

Intertwining Regulatory, Commercial and Patient-Safety Information:

  • How regulatory complexities affect device manufacturers
  • Ways manufacturers can work with stakeholders to guide and manage information
  • National and local regulatory concerns: counterfeits, traceability, cost controls

Initial Development, Maintenance and Reuse of Information:

  • Supporting global use-cases

UDI Best Practices:

  • EU UDI requirements, including EUDAMED expectations

Finding the best way to meet shifting global identification obligations is a complicated balancing act. Learn how to navigate the process and discover the most effective, practical solutions to international UDI concerns.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Meeting Global Unique Device Identification Requirements:

Regulation, Compliance, and Best Practices

An FDAnews Webinar

Wednesday, July 29, 2020, 1:30 p.m.-3:00 p.m. EDT

https://www.fdanews.com/udirequirements

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/udirequirements

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

Unique Ziosoft AI Platform Exceeds 2,500 Installations in More Than 30 Countries Globally


The company will make free Covid-19 advanced visualization software available at no charge. Interested clinicians can visit Ziosoft’s virtual ECR booth #525 and request access to this software

Ziosoft, a pioneer in 3D/4D AI medical visualization, is featuring its comprehensive suite of advanced visualization and post-processing applications, on a true vendor neutral platform, at the annual European College of Radiology (ECR) being held virtually from July 15 – 19, 2020. With over 2,500 installations in 2,000 locations throughout more than 30 countries globally, the company is also highlighting PhyZiodynamics™ in Vivo, which enables virtual dynamic dissection to support precise therapy for organ targeting analyses and Implantations.

“PhyZiodynamics in Vivo offers an unprecedented “real-time” journey through the body non-invasively, supporting diagnoses and treatment planning for a wide variety of organ targets,” said Rajeev Taitriya, vice president, Business Development and Marketing for Ziosoft. “Whether for brain, lungs, or other regions of interest, PhyZiodynamics in Vivo, is an advanced 4D processing system, allowing the automated registration of DICOM-based modality images into true fidelity 3D and 4D organ data sets. These data sets then can be interactively interrogated throughout the entire structure while either still or in motion.”    

Taitriya also indicated the company will make free Covid-19 advanced visualization software available at no charge. Interested clinicians can visit Ziosoft’s virtual ECR booth and request access to this software.

Ziosoft’s AI platform provides a robust and clinically validated algorithm, which is driven by both a traditional and new era of machine learning, unlocking the potentials of artificial intelligence (AI) for efficient and repeatable outcomes. The company’s flagship Ziostation2 is an economical and scalable multi-departmental solution. A full suite of regulatory cleared 2D, 3D, and 4D analytical tools provides consistent functionality across the enterprise, without compromise. It provides a vendor-neutral advanced visualization platform across multiple imaging modalities. It is also based on architecture that is designed to grow with the future needs of clinicians.

“We use 20 plus years of medical imaging expertise with deep learning to enable accurate segmentation with easy-to-use intuitive tools for efficient and customizable workflows,” said Shusuke Chino, co-founder and president, Ziosoft. “This experience has not only brought outstanding 3D/4D to the radiological community, but several other useful tools including 3D printing which can be used in numerous planning endeavors. We look forward to continuing our ongoing developments to expand our AI-enabled visualization platform.”

About Ziosoft, Inc.

Ziosoft provides a comprehensive multi-modality, advanced processing and viewing solution for any specialty. Its customizable platform provides automated workflow to maximize efficiency. It is also a scalable, enterprise platform for “anywhere” accessibility and, as a software-only platform, it is simplified to minimize cost of ownership. For further information, visit http://www.ziosoftinc.com.

Share article on social media or email:

Author Alan Foster’s newly released “Someone Must Die” is the thrilling tale of how a group of missionaries saved an Amazonian tribe from near certain extinction


News Image

“Someone Must Die”: a gripping, startling, and breathtaking tale of the efforts of a group of courageous missionaries to save two bands of a nomadic Amazonian tribe from annihilation by the people encroaching on their territory. “Someone Must Die” is the creation of published author, Alan Foster, who was raised by missionary parents in the Bolivian Amazon.

Foster writes: “As missionaries, our concern goes beyond preserving the body, since man’s eternal relationship with God is of the greatest importance. Much of the story is compiled from journals and letters written by my father, Les Foster, or from my journals, letters, and memories about our experiences, along with our many missionary colleagues, in befriending and helping the once hostile nomads settle down.”

Published by Christian Faith Publishing, Alan Foster’s new book is the incredible true story of how two small bands of hostile nomads, now known as the Yuquí, were befriended by a group of courageous missionaries who placed their trust fully in God. Day after day, the missionaries put their lives at risk in the western Bolivian Amazon in order to make friends with the jungle dwellers, thus sparing the tribe from annihilation by those who were invading their territory.

View a synopsis of “Someone Must Die” on YouTube.

Consumers can purchase “Someone Must Die” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Someone Must Die”, contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Five join New England College of Optometry’s Board of Trustees


Professional photo of Janet LaBreck.

Janet LaBreck

New England College of Optometry (NECO) announces five new members to its Board of Trustees. The board is responsible for NECO’s educational mission and fiscal oversight.

The new trustees are Linda Bennett, OD, founder of Bennett Family Eye and former President of the Massachusetts Society of Optometrists; Katherine Coffey, OD, founder of Coffey Eye Care and former president of the Massachusetts Society of Optometrists; Alan Glazier, OD, founder of ODs on Facebook; Janet LaBreck, former Obama White House Commissioner of the Rehabilitation Services Administration and first Black Commissioner for the Massachusetts Commission for the Blind; and Valarie Ricciardi, OD, practitioner with and administrator of Central Massachusetts Vision Source as well as Vision Source Regional Administrator.

Linda Bennett, OD — Dr. Bennett founded Bennett Family Eye in Belmont, MA, and in the span of 30 years, through sophisticated marketing and acquisitions, grew it from a single practitioner model to multiple providers and locations. Prior, she worked in private practice in Charlestown, MA, at Harvard Community Health Center, and at Cambridge City Hospital. In addition to practicing optometry, Dr. Bennett served as President of the Massachusetts Society of Optometrists and for five years on the Massachusetts Board of Registration of Optometry. Dr. Bennett graduated from New England College of Optometry and served two terms as President of NECO’s Alumni Association.

Katherine Coffey, OD – Dr. Coffey founded Coffey Eye Care in Quincy, MA in 1992, and expanded the practice notably until partnering with MyEyeDr in 2020. She is active in the Massachusetts Society of Optometrists and served as its President and Legislative Committee member. Dr. Coffey was an adjunct faculty member at NECO and was previously a staff optometrist specializing in contact lenses at the Massachusetts Eye and Ear Infirmary. She served on the Board of Trustees of Elizabeth Seton Academy in Dorchester, MA. Dr. Coffey is a graduate of New England College of Optometry and holds a master’s degree in chemistry from Boston College.

Alan Glazier, OD – Named as one of the most influential optometrists, Dr. Glazier is the founder of ODs on Facebook and ODsOnFB.com, the eye care industry’s largest and most highly engaged eye care organization online. He is inventor on seven issued patents in computer science and ophthalmology. Dr. Glazier is well-published, lectures nationally and internationally, and serves on multiple advisory boards. He was named Optometrist of the Year in the state of Maryland. Dr. Glazier is the founder of Shady Grove Eye and Vision Care in Rockville, Maryland and partner and business development executive in Keplr Vision. He is a graduate of New England College of Optometry and delivered the NECO 2019 Commencement address.

Janet LaBreck – Former Commissioner LaBreck is a nationally recognized senior executive and presenter with more than 28 years of success in implementing strategies for integrated solutions within the Federal and State government and the business community. Appointed by President Barack Obama as Commissioner of the Rehabilitation Services Administration in the U.S. Department of Education, LaBreck supported states and other agencies in providing vocational rehabilitation services to individuals with disabilities in order to maximize their employment, independence and integration into the community and workforce. Prior to this appointment, she served for six years as Commissioner for the Massachusetts Commission for the Blind. LaBreck currently works at Synergy Consulting Partners LLC, which she co-founded in 2017.

In 2017, NECO dedicated the Janet L. LaBreck Center for Low Vision Rehabilitation clinic in her honor in recognition of her commitment and dedication to the field of blindness. NECO bestowed her with an Honorary Doctorate of Humane Letters.

Valarie A. Ricciardi, OD – Dr. Ricciardi has been providing primary eye care for all ages, including contact lenses and laser vision consultations for over 28 years. She practices in two locations, Spencer and Worcester, and is an administrator for Massachusetts Vision Source for which she was awarded Administrator of the Year. She is a member of the American Optometric Association and secretary of the Massachusetts Society of Optometrists. Dr. Ricciardi is a graduate of the New England College of Optometry and Assumption College.

Share article on social media or email:

Navigating the Intersection Between Regulatory Requirements & Risk Management Webinar July 29, 2020


WCG FDAnews Logo

WCG FDAnews Logo

Pharmaceutical Quality Risk Management

Navigating the Intersection Between Regulatory Requirements & Risk Management

An FDAnews Webinar

Wednesday, July 29, 2020, 11:00 a.m.-12:30 p.m. EDT

https://www.fdanews.com/pharmaqrk

Risk is everywhere. And growing. Struggling to manage the types — and severity — of risk with Quality Risk Management (QRM) techniques?

QRM must be applied consistently to an ever-increasing roster of drug development, manufacturing, distribution, and inspection and submissions review processes. If one is exerting a huge effort but still feels adrift, this webinar is the answer.

Amanda McFarland, a QRM and microbiology senior consultant with ValSource, Inc., will explain the regulations relative to risk management and explain how to apply QRM’s principles to achieve compliance and maintain a competitive advantage. She will:


  • Discuss best practices related to QRM program development and execution, including process, people and documentation
  • Demonstrate ways to integrate QRM into quality systems such as change control and investigations and how integration can benefit an organization
  • Explore the PIC/S Aide-Memoire on QRM and how one can prepare for an inspection of a QRM program
  • Evaluate the risk management tools available to meet regulatory requirements, such as process hazard analysis (PHA), risk evaluation and mitigation (REM), hazard analysis critical control point (HACCP), and failure mode and effects analysis (FMEA)
  • Recognize the critical QRM regulations that apply to pharma such as ICH 9, ICH Q10, ISO 14644 and Annex 1

Given that organizations have made or are currently making decisions about how to maintain production levels in light of the novel coronavirus, this is an incredible opportunity: Ms. McFarland will assist one in exploring the risks and applying risk-based decisionmaking to ensure the long-term impacts of a company’s current decisions are fully understood.

Come away with the tools needed to ensure the QRM works to keep one compliant and moving forward.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.

Webinar Details:

Pharmaceutical Quality Risk Management

Navigating the Intersection Between Regulatory Requirements & Risk Management

An FDAnews Webinar

Wednesday, July 29, 2020, 11:00 a.m.-12:30 p.m. EDT

https://www.fdanews.com/pharmaqrk

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/pharmaqrk

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

Renodis CEO Joins American Cancer Society Nationwide CEO Fitness Challenge July 16


Cancer is a serious health issue for many families and a top workplace issue for many businesses, costing U.S. employers billions of dollars in expenses productivity losses each year. I’m honored to participate in the Fit2BeCancerFree CEO challenge.

Renodis, a leading telecom and mobility management firm, today announced its CEO, Craig Beason, will join 7 other Twin Cities CEOs in American Cancer Society’s Fit2BeCancerFree® virtual fitness challenge on July 16th as part of his commitment to the CEOs Against Cancer® program and promoting cancer prevention in the workplace.

“Creating a world free from cancer can start in the workplace when we inspire our employees to live healthy and active lifestyles,” said Gary M. Reedy, CEO for the American Cancer Society. “About half of cancer deaths could be prevented if everyone lived a healthy lifestyle, including not smoking and maintaining a healthy weight. The Fit2BeCancerFree challenge is designed to encourage corporate leaders to lead by example, inspiring more activity among their employees throughout their workday, and helping us make a measurable difference in saving lives from cancer.”

The American Cancer Society currently has 15 active CEOs Against Cancer chapters nationwide with about 400 members. The CEOs Against Cancer program unites CEOs from the world’s top companies to raise awareness of high-impact cancer mission areas and collaborate with other business leaders to create a culture of health in their organizations and communities.

CEOs Against Cancer members who participate in the challenge will sync a fitness tracker to a live event leaderboard powered by Movespring and hosted on cancer.org. The leaderboard will track results of the top participants throughout the day of the challenge, and the participant with the most steps logged will receive bragging rights and national recognition.

“As CEOs we play a critical role in partnering with the American Cancer Society to make an impact on the fight against cancer in our communities and across the country,” states Craig Beason, CEO of Renodis and member of CEOs Against Cancer Twin Cities. “Cancer is a serious health issue for many families and a top workplace issue for many businesses, costing U.S. employers billions of dollars in expenses productivity losses each year. I’m honored to participate in the Fit2BeCancerFree CEO challenge. Through a bit of friendly competition, we can motivate employees across our companies to get moving and together we can save more lives from cancer.”

About Renodis

Renodis is a Telecom and Mobility Management Company trusted by businesses to solve telecom and mobility frustrations — saving time, money, and enabling better technology choices and superior service. This is accomplished through innovative processes, purpose-built systems, talented people, and deep industry relationships. Firms such as Land O’Lakes, Red Wing Shoe Company, Northern Tool + Equipment, Fairview, Lifetime, Cambria, Menards, Romano’s Macaroni Grill, and hundreds of other firms experience peace of mind knowing their Telecom and Mobility environments are professionally managed. Find out more at http://www.renodis.com.

About the American Cancer Society

The American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer. From breakthrough research, to free lodging near treatment, a 24/7/365 live helpline, free rides to treatment, and convening powerful activists to create awareness and impact, the Society is the attacking cancer from every angle. For more information go to http://www.cancer.org.

Share article on social media or email:

Genetic Editing Milestone in Mouse Model of Rett Syndrome


John Sinnamon, PhD and Gail Mandel, PhD

The study is the first example of RNA editing in a mouse model of a neurological disease, and therefore a considerable step forward in the potential of RNA editing becoming a therapeutic for Rett Syndrome,” Monica Coenraads, Rett Syndrome Research Trust

A genomic error that causes Rett Syndrome, a serious lifelong neurological disorder, can be corrected in the brains of mice by rewriting the genetic instructions carried by the RNA.

The new research, published July 14 in the journal Cell Reports, shows that RNA editing may repair the underlying cause of Rett Syndrome in a mouse model. The technology recoded enough RNA to restore half of the normal protein in three different kinds of neurons in the Rett mouse.

The results represent a promising early step in using RNA editing to treat Rett Syndrome, a disorder that affects about 350,000 individuals worldwide. The authors in the neuroscience lab of Gail Mandel at the Vollum Institute at Oregon Health and Science University (OHSU) in Portland, caution however, that much work lies ahead to advance the potential therapeutic to the clinic.

“This was a proof of principle” that the technique works in the brain, says lead author John Sinnamon.

People diagnosed with Rett Syndrome have mutations in a gene called MECP2. The gene makes a protein that is abundant in brain cells and controls the activity of many other genes.

Disease symptoms usually appear between 12 and 18 months of age and can include loss of speech and purposeful hand use, respiratory problems, motor deficits, seizures, and gastrointestinal and orthopedic issues. No cure exists, but studies in mice suggest restoring healthy MeCP2 protein function can dramatically reverse the condition.

Hundreds of different mutations in the MECP2 gene have been found in people with Rett Syndrome. The instructions for the protein it makes are coded in a unique combination of four genomic “letters” — A, C, G and T. The cell transcribes the DNA code into RNA and then into protein.

The idea behind the strategy used in this new study is to produce a healthy MeCP2 protein by repairing or “editing” the genetic error in the RNA.

The team used a mouse model of a human MECP2 mutation in which a single letter is wrong, an A where a G should be. They adapted an RNA editing technique by designing a guide to recognize the mutated section and change the A back to the normal G.

In 2017, Sinnamon, Mandel, and their colleagues reported their first success with the RNA approach, efficiently repairing the Rett mouse mutant RNA in developing neurons in a lab dish. In the new study, the team expanded on these results. They asked three questions: Is it possible to edit MeCP2 RNA in several different types of neurons in adult mice in vivo? If so, what types of neurons can be edited? Does editing restore MeCP2 protein function?

To address these questions, the researchers packaged a mouse Mecp2 RNA guide and human editing enzyme (the “editase”) in a viral vector and introduced it directly into the hippocampus, a well-studied brain structure associated with learning and memory.

The injected editase repaired about half of the RNA produced by the mutant MeCP2 gene in each of three types of neurons located in different regions of the hippocampus and, importantly, MeCP2 protein function was equally repaired in the neurons.

“It is encouraging that this RNA editing approach seems to be efficacious in different types of neurons in the brain,” says Mandel, the senior author whose lab has pioneered the concept of RNA editing in Rett Syndrome. A similar repair rate should be achievable throughout the brain, the researchers believe, if a vector can be delivered diffusely throughout the brain.

“In the next set of experiments,” Mandel says “we will administer the virus by blood, so that the entire brain is subject to editing. This will allow us to monitor whether there is any amelioration of Rett symptoms in the mice.”

As a strategy to restore the normal function of MECP2, the single-base RNA editing approach of swapping out A and G could address about 40% of all known mutations that cause Rett Syndrome, Sinnamon says.

The researchers reported that RNA of genes other than Mecp2 also were inadvertently edited, known as off-target effects. It is unknown what, if any, effect the off-target edits had in the mice. The experimental treatment appeared to cause no harm to the mice over the study time period.

As the RNA editing approach progresses through experimental steps, additional questions will need to be answered. “We need to know how much MECP2 RNA we need to repair in an individual cell and in how many cells in the nervous system,” Mandel says.

Her research group and others in the editing field also want to learn more about how to increase editing efficiency while diminishing off-target effects. “There are many bright and determined investigators working on these problems,” she says. “My hope is this paper will stimulate these creative minds even further. We are trying to take advantage of what’s happening in the field in real time and apply the emerging optimizations to Rett and other neurological diseases.

“The study is the first example of RNA editing in a mouse model of a neurological disease, and therefore a considerable step forward in the potential of RNA editing becoming a therapeutic for Rett Syndrome,” says Monica Coenraads, executive director of Rett Syndrome Research Trust, which helped fund the study. “Strategies that edit the mutation are an elegant way of addressing the problem. This exciting progress would not be possible without all of RSRT’s supporters and the affected families that are so dedicated to raising funds for us.”

RSRT funds six genetic approaches to restore a functioning MeCP2 protein in patients with disease causing mutations. Beyond RNA editing, other approaches are gene replacement, which is the closest to the clinic, gene editing, RNA trans-splicing, protein replacement and reactivation of the silent MeCP2 on the inactive X.

The study was funded by the Rett Syndrome Research Trust and the National Institutes of Health. Mandel is a scientific co-founder of Vico Therapeutics, a biotech company working on non-viral approaches to edit RNA in Rett syndrome and other neurological conditions.

About Rett Syndrome Research Trust

The Rett Syndrome Research Trust (RSRT) is a non-profit organization with a highly personal and urgent mission: a cure for Rett Syndrome and related MECP2 disorders. RSRT operates at the nexus of global scientific activity enabling advances in knowledge and driving innovative research. Since its founding in 2008, RSRT has awarded $66 million, all of it contributed by affected families and their networks, to leading scientists. To learn more, please visit http://www.reverserett.org.

Publication Link

https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30859-7

EagleView Appoints Technology Industry Veteran Chris Jurasek as Chief Executive Officer


EagleView CEO Chris Jurasek

Jurasek brings more than 25 years of experience leading global software and industrial technology companies and a track record of driving innovation to generate long-term value, customer engagement and sustainable growth.

EagleView, a leading technology provider of aerial imagery, data analytics and GIS solutions, today announced the appointment of Chris Jurasek as Chief Executive Officer, effective immediately. In this role, he will drive the company’s customer-focused product innovation and market expansion strategies. Rishi Daga, who has served as CEO since 2016 and led the company’s growth for more than 10 years, will assume the role of Vice Chairman, where he will focus on cultivating EagleView’s customer relationships.

Jurasek brings more than 25 years of experience leading global software and industrial technology companies and a track record of driving innovation to generate long-term value, customer engagement and sustainable growth. He most recently served as President of JetSmarter, and prior to that, he held the roles of President and CEO of Calero Software. Jurasek has been an Operating Executive for Clearlake Capital Group, L.P. (“Clearlake”) since 2014. He earned his MBA from the Kellogg School of Management at Northwestern University and holds a bachelor’s degree from Bowling Green State University.

“EagleView was a first mover in identifying the potential and developing the technology to utilize aerial imagery to deliver unique innovations to customers across a wide range of industries,” Jurasek said. “I am proud to join Rishi and this outstanding team as we double down on creating exciting product solutions for customers in our current verticals of roofing & construction, insurance, government, utilities and solar, as well as developing new use cases to leverage our industry-leading image capture platform.”

EagleView is a pioneer in aerial property measurements, with the most extensive and up-to-date coverage in the U.S. In just the six months ended June 30, 2020, the company achieved a milestone of 100 million images processed, more than doubling its 2019 full year figure. EagleView is backed by Clearlake and Vista Equity Partners.

Daga’s duties as Vice Chairman will focus on growth and strategy, including direct leadership and management of all go-to-market activities and support of all EagleView growth opportunities by providing identification of customer needs, contributions to product roadmap and execution of new product launch activities.

Daga welcomed Jurasek, noting, “The EagleView team is ready to fly even higher in delivering customer solutions, and we welcome Chris’ leadership as we enter this next phase of growth and innovation. I am excited to work with Chris, and to continue strategically supporting our customers to meet their needs and exceed their expectations.”

About EagleView

EagleView is a leader in aerial imagery, machine learning-derived data analytics and software, helping customers in different industries use property insights for smarter planning, building and living. With more than 200 patents, EagleView pioneered the field of aerial property measurements and has the largest multi-modal image database in history, covering 98 percent of the U.S. population. Flying over 9.5 million linear miles every year, EagleView’s coverage is the most extensive and up to date, enabling local government and business customers to use the most accurate data to make timely and informed decisions. For more information, call (866) 659-8439, visit http://www.EagleView.com and follow @EagleViewTech.

Share article on social media or email: